New drug combo aims to save kidneys in rare bladder cancer
NCT ID NCT05656235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests two drugs—enfortumab vedotin and pembrolizumab—in 20 people with high-grade upper tract urothelial cancer who cannot or choose not to have surgery to remove the kidney and ureter. The goal is to see if the combination can control the cancer and preserve kidney function over one year. Participants receive the drugs intravenously every three weeks for up to 35 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enfortumab vedotin (Padcev) and pembrolizumab (Keytruda)
What this could lead to
If successful, this drug combination could offer a non-surgical option to control high-grade upper tract urothelial cancer, potentially preserving kidney function.
What could go wrong
This is a small, early-phase trial with only 20 participants. The drugs may cause side effects like nerve damage or immune reactions, and the cancer might still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University: Sibley Memorial Hospital
RECRUITINGWashington D.C., District of Columbia, 20016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact